Trial · NCT03480243
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 40
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Medical device site reaction | General disorders | Padsevonil (Period 1+2) (FAS) | 5 | 28 | 5 |
| other | Medical device site reaction | General disorders | Erythromycin (Period 3a) (FAS) | 0 | 27 | 0 |
| other | Medical device site reaction | General disorders | Padsevonil and Erythromycin (Period 3b) (FAS) | 7 | 27 | 7 |
| other | Medical device site reaction | General disorders | Erythromycin (Period 3c) (FAS) | 0 | 26 | 0 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Padsevonil (Period 1+2) (FAS) | 3 | 28 | 3 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Erythromycin (Period 3a) (FAS) | 0 | 27 | 0 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Padsevonil and Erythromycin (Period 3b) (FAS) | 0 | 27 | 0 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Erythromycin (Period 3c) (FAS) | 0 | 26 | 0 |
| other | Dizziness | Nervous system disorders | Padsevonil (Period 1+2) (FAS) | 18 | 28 | 27 |
| other | Dizziness | Nervous system disorders | Erythromycin (Period 3a) (FAS) | 0 | 27 | 0 |
| other | Dizziness | Nervous system disorders | Padsevonil and Erythromycin (Period 3b) (FAS) | 8 | 27 | 8 |
| other | Dizziness | Nervous system disorders | Erythromycin (Period 3c) (FAS) | 0 | 26 | 0 |
| other | Headache | Nervous system disorders | Padsevonil (Period 1+2) (FAS) | 5 | 28 | 6 |
| other | Headache | Nervous system disorders | Erythromycin (Period 3a) (FAS) | 0 | 27 | 0 |
| other | Headache | Nervous system disorders | Padsevonil and Erythromycin (Period 3b) (FAS) | 0 | 27 | 0 |
| other | Headache | Nervous system disorders | Erythromycin (Period 3c) (FAS) | 2 | 26 | 2 |
| other | Paraesthesia | Nervous system disorders | Padsevonil (Period 1+2) (FAS) | 2 | 28 | 2 |
| other | Paraesthesia | Nervous system disorders | Erythromycin (Period 3a) (FAS) | 0 | 27 | 0 |
| other | Paraesthesia | Nervous system disorders | Padsevonil and Erythromycin (Period 3b) (FAS) | 0 | 27 | 0 |
| other | Paraesthesia | Nervous system disorders | Erythromycin (Period 3c) (FAS) | 0 | 26 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03480243/events